Chemed Exceeds Q1 Expectations, Lifts Full-Year EPS Guidance
Summary
Chemed Corporation reported strong first-quarter results, with revenue of $657.50 million and adjusted EPS of $5.65, both surpassing analyst estimates. Building on this performance, the company raised its full-year adjusted EPS guidance to a new range of $24.00-$24.75. This positive earnings beat and outlook upgrade, driven by robust performance in its VITAS Healthcare segment, is a significant catalyst for the stock. The news follows the company's recent renewal of its $450 million credit facilities, further strengthening its financial position. Traders will be watching for continued growth in VITAS and how the company manages the noted headwinds in its Roto-Rooter segment.
At the time of this announcement, CHE was trading at $397.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $365.21 to $593.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.